The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Scientists speculate that Semaglutide, as a GLP-1 receptor analog, represents a peptide with broad research potential beyond ...

The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries ...

aNottingham Digestive Diseases Centre (NDDC), Translational Medical Sciences, School of Medicine, University of Nottingham, NG7 2UH, UK bNIHR Nottingham Biomedical Research Centre, Nottingham ...

Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MBX), a ...

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).